Sofpironium bromide - Botanix SB
Alternative Names: BBI-4000; ECCLOCK; ECCLOCK® Gel 5%; SOFDRA; SOFDRA GEL; sofpironium bromide gel, 15% - Brickell BiotechLatest Information Update: 28 Nov 2023
At a glance
- Originator Bodor Laboratory
- Developer Bodor Laboratory; Botanix Pharmaceuticals; Brickell Biotech; Dong Wha Pharmaceutical; Kaken Pharmaceutical
- Class Cyclopentanes; Phenylacetates; Pyrrolidines; Skin disorder therapies; Small molecules
- Mechanism of Action Acetylcholine inhibitors; Cholinergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hyperhidrosis
- Preclinical Chronic obstructive pulmonary disease
Most Recent Events
- 28 Nov 2023 Botanix Pharmaceuticals expects approval of New Drug Application (NDA) in USA in mid-2024 (Botanix Pharmaceuticals pipeline, November 2023)
- 27 Sep 2023 Preregistration for Hyperhidrosis in South Korea (Topical)
- 21 Jul 2023 Fresh Tracks Therapeutics and Botanix Pharmaceuticals amend the purchase agreement for sofpironium bromide